<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348006</url>
  </required_header>
  <id_info>
    <org_study_id>AR200103</org_study_id>
    <secondary_id>SEANM</secondary_id>
    <nct_id>NCT04348006</nct_id>
  </id_info>
  <brief_title>Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients</brief_title>
  <acronym>MM</acronym>
  <official_title>Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Rasheed University College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baghdad Medical City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Al-Rasheed University College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bortezomib considered the standard of care for treating multiple myeloma patients, we aimed
      to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly
      diagnosed patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment the safety of Alvocade® therapy</measure>
    <time_frame>During 6 months</time_frame>
    <description>Monitoring the rate of any adverse effect/event that will occur during the induction therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment the effecacy of Alvocade® therapy</measure>
    <time_frame>At end of 6 months</time_frame>
    <description>Assessment of overall response rate (ORR) of treatment after completion of induction protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First assessment response</measure>
    <time_frame>At end of 2 months</time_frame>
    <description>Assessment of response rate after 2 cycle from starting treatment protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second assessment response</measure>
    <time_frame>At end of 4 months</time_frame>
    <description>Assessment of response rate after 4 cycle from starting treatment protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Third assessment response</measure>
    <time_frame>At end of 6 months</time_frame>
    <description>Third assessment response after 6th cycle protocol (if there is no response or get less than VGPR after 4th cycle)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Newly Diagnosed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Induction Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib will be administered as part of VCD or VRD protocols</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib 3.5 MG</intervention_name>
    <description>VCD protocol
V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)
C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)
D, Dexamethasone oral: 40mg (days 1 to 4)
VRD protocol:
V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)
R, Lenalid® cap 25 mg po (day 1 to 21)
D, Dexamethasone oral: 40mg (days 1 to 4)</description>
    <arm_group_label>Induction Therapy</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Dexamethasone</other_name>
    <other_name>lenalidomide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A:
             anemia, and B: bone lesions)

          -  Age above 18 years old

        Exclusion Criteria:

          -  Age below 18 years

          -  Smoldering MM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali M Jawad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bassam F Matti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad Medical City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tareq A Saleh, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Baghdad Medical City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahammed S Abbas, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Baghdad Medical City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed K Al-Qayyim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad Medical City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alaaldin S Naji, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ammer F Majid, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad Medical City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adil S Al-Oqaby, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad Medical City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mazin A Shubir, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad Medical City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hawraa D Jumaa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghdad Medical City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hayder A Fawzi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Al-Rasheed University College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tareq A Saleh, PhD</last_name>
    <phone>07738293183</phone>
    <phone_ext>964</phone_ext>
    <email>tariqyamanmed@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hayder A Fawzi, PhD</last_name>
    <phone>07722629743</phone>
    <phone_ext>+964</phone_ext>
    <email>hayder.adnan2010@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baghdad Hematology center - Baghdad Medical City</name>
      <address>
        <city>Baghdad</city>
        <state>Bab-Almuadham</state>
        <zip>12221</zip>
        <country>Iraq</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tareq A Saleh, PhD</last_name>
      <phone>07738293183</phone>
      <phone_ext>964</phone_ext>
      <email>tariqyamanmed@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Bassam F Matti, PhD</last_name>
      <phone>07702052345</phone>
      <phone_ext>964</phone_ext>
      <email>bassam_francis@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tareq A Saleh, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bassam F Matti, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed K Al-Qayyim, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahammed S Abbas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alaaldin S Naji, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ammer F Majid, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adil S Al-Oqaby, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mazin A Shubir, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hawraa D Jumaa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali M Jawad, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

